Harmony Biosciences Holdings Inc (HRMY) Reports Robust Revenue Growth in Q4 and Full Year 2023

Net Revenue: Q4 net revenue increased by 31% to $168.4 million; full-year net revenue rose by 33% to $582.0 million. GAAP Net Income: Q4 GAAP net income was $26.6 million; full-year GAAP net income reached $128.9 million. 2024 Revenue Guidance: Projected net product revenue between $700 million to $720 million.

Related Keywords

,Jeffreym Dayno ,Harmony Biosciences Holdings Inc ,Harmony Bioscience President ,Financial Metrics ,Harmony ,Product Revenue ,Revenue Growth ,Neurological Diseases ,Net Revenue ,Oakix ,